 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• U.S. News
Johnson & Johnson Unit Submits HIV Drug Candidate to FDA for ApprovalJuly 20, 2007 On Wednesday, Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division said it had filed a new application for Food and Drug Administration approval of TMC125 (etravirine), its new HIV drug candidate. FDA's decision to fast-track TMC125 means the company can submit data as it becomes available, rather than all at once. The treatment for people infected with HIV-1 is meant to be administered with other antiretrovirals. Back to other news for July 2007 Associated Press 07.18.2007 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
E-Mail
Printable Single-Page
Glossary
Share
